(Z)-7-[(1S,4S,6S)-6-[(E,3S)-3-Hydroxyoct-1-enyl]-2-oxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (Z)-7-[(1S,4S,6S)-6-[(E,3S)-3-Hydroxyoct-1-enyl]-2-oxabicyclo[2.2.1]heptan-5-yl]hept-5-enoic acid
• 化学式: C₂₁H₃₄O₄
• 分子量: 350.5
• InChiKey: LQANGKSBLPMBTJ-WTPHSRJXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Preventive and/or Therapeutic Agent for Diabetic Vascular Disorder and Respiratory Disorder
  申请人：Satoh Keisuke

  公开号：US20080312336A1

  公开（公告）日：2008-12-18

  The present invention provides preventive and/or therapeutic agents for either one, or both, of a diabetic vascular disorder and a diabetic respiratory disorder comprising, as an active ingredient, a cyclohexenone long chain alcohol compound represented by the following formula (1): [wherein R 1 , R 2 , and R 3 each represent a hydrogen atom or a methyl group, and X represents a linear or branched C10-C28 alkylene or alkenylene group]. Since the cyclohexenone long chain alcohol of formula (1) improves diabetic vascular smooth muscle contraction and bronchial smooth muscle contraction, it is useful as a preventive and/or therapeutic agent for a diabetic vascular disorder or a respiratory disorder.

  本发明提供了预防和/或治疗糖尿病血管疾病和糖尿病呼吸道疾病的预防和/或治疗剂，其活性成分为以下式（1）所表示的环己烯酮长链醇化合物： [其中R1、R2和R3分别表示氢原子或甲基基团，X表示线性或支链C10-C28烷基或烯基基团]。 由于式（1）中的环己烯酮长链醇改善了糖尿病血管平滑肌收缩和支气管平滑肌收缩，因此它可用作糖尿病血管疾病或呼吸道疾病的预防和/或治疗剂。
• METHODS FOR THE TREATMENT AND DIAGNOSIS OF BONE MINERAL DENSITY RELATED DISEASES
  申请人：INSERM - Institut National de la Santé et de la Recherche Médicale

  公开号：EP2227560B1

  公开（公告）日：2017-10-18
• Methods for the Treatment and Diagnosis of Bone Mineral Density Related Diseases
  申请人：Cormier-Daire Valerie

  公开号：US20100284991A1

  公开（公告）日：2010-11-11

  The present invention relates to methods of the treatment and diagnosis of bone mineral density related disorders. More particularly, the present invention relates to a method of diagnosing or predicting a bone mineral density related disease, or a risk of a bone mineral density related disease, in a subject, which method comprises detecting a mutation in the TBXAS1 gene, wherein the presence of said mutation is indicative of a bone mineral density related disease or of a risk of a bone mineral density related disease. The invention also relates to a compound selected in the group consisting of a thromboxane synthase (TXAS) encoding polynucleotide, a TXAS, thromboxane A2 or an analog thereof for treating or preventing a disease associated with an increased bone mineral density (e.g., Ghosal hematodiaphyseal dysplasia syndrome). The invention also relates to a compound selected from the group consisting of an inhibitor of TBXAS1 gene expression or a thromboxane inhibitor for treating or preventing a disease associated with a decreased bone mineral density (e.g., osteoporosis).
• US9834820B2
  申请人：——

  公开号：US9834820B2

  公开（公告）日：2017-12-05